News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,223 Results
Type
Article (41928)
Company Profile (435)
Press Release (664860)
Section
Business (208558)
Career Advice (2016)
Deals (35984)
Drug Delivery (98)
Drug Development (83450)
Employer Resources (170)
FDA (16373)
Job Trends (15064)
News (352416)
Policy (33015)
Tag
Academia (2620)
Alliances (50829)
Alzheimer's disease (1347)
Approvals (16332)
Artificial intelligence (205)
Bankruptcy (365)
Best Places to Work (11838)
Biotechnology (329)
Breast cancer (223)
Cancer (1676)
Cardiovascular disease (132)
Career advice (1681)
CAR-T (121)
Cell therapy (350)
Clinical research (66909)
Collaboration (662)
Compensation (356)
COVID-19 (2616)
C-suite (156)
Data (1566)
Diabetes (208)
Diagnostics (6308)
Earnings (86452)
Employer resources (147)
Events (114185)
Executive appointments (555)
FDA (17233)
Funding (595)
Gene therapy (247)
GLP-1 (677)
Government (4439)
Healthcare (19083)
Infectious disease (2722)
Inflammatory bowel disease (122)
Interviews (309)
IPO (16720)
Job creations (3698)
Job search strategy (1431)
Layoffs (461)
Legal (7958)
Lung cancer (250)
Manufacturing (236)
Medical device (13396)
Medtech (13401)
Mergers & acquisitions (19597)
Metabolic disorders (561)
Neuroscience (1765)
NextGen: Class of 2025 (6749)
Non-profit (4546)
Northern California (2005)
Obesity (319)
Opinion (209)
Patents (144)
People (58137)
Phase I (21014)
Phase II (29540)
Phase III (21824)
Pipeline (672)
Postmarket research (2600)
Preclinical (8958)
Radiopharmaceuticals (257)
Rare diseases (327)
Real estate (6002)
Regulatory (22307)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1747)
Startups (3753)
United States (18250)
Vaccines (620)
Weight loss (222)
Date
Today (103)
Last 7 days (627)
Last 30 days (2549)
Last 365 days (35745)
2025 (3493)
2024 (36299)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47420)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32186)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27994)
Location
Africa (733)
Arizona (216)
Asia (38871)
Australia (6470)
California (4657)
Canada (1654)
China (389)
Colorado (211)
Connecticut (225)
Europe (84796)
Florida (664)
Georgia (159)
Illinois (464)
Indiana (255)
Maryland (735)
Massachusetts (3638)
Michigan (196)
Minnesota (333)
New Jersey (1318)
New York (1322)
North Carolina (876)
Northern California (2005)
Ohio (168)
Pennsylvania (1074)
South America (1107)
Southern California (1747)
Texas (681)
Utah (139)
Washington State (472)
707,223 Results for "nuvig therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.
December 5, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
December 5, 2024
·
4 min read
Biotech Bay
Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089
Nuvig Therapeutics, Inc. today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease.
February 12, 2024
·
2 min read
Business
Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer
Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.
October 4, 2023
·
2 min read
Business
Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, announced the appointment of Julie Anne Smith as Chief Executive Officer and member of the Board of Directors.
January 4, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer
Nuvig Therapeutics, Inc. announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer.
August 15, 2022
·
2 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Press Releases
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
February 4, 2025
·
7 min read
Biotech Bay
Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases
Nuvig Therapeutics, Inc. , announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function.
May 11, 2022
·
3 min read
1 of 70,723
Next
